CD274 and non-small cell lung carcinoma: Considering that PDAC has a lower mutation burden, it is not surprising that we found only 4 to 12% PD-L1 positive tumors compared to the reported 83% in melanoma, 50% in NSCLC and 80% in RCC [10].